Pulmonary hypertension (PH) is a potentially life-threatening condition caused by high blood pressure in the arteries of the lungs. The condition can lead to death from heart failure within a few years. BHF has funded almost 200 research grants into PH worth over £40m since the 1960s.
Discovering new knowledge
Our researchers have discovered more about the causes of PH. They’ve helped to find the genes causing a type of inherited pulmonary hypertension. This led to the development of new drugs which target the effects of the genetic changes.
Developing new technology
BHF-funded research has helped develop new ways to diagnose the condition. For example, researchers have developed new imaging techniques. These could replace the need for more invasive tests in the diagnosis and treatment of PH.
Influencing clinical practice
BHF-funded research has contributed to changing how we treat people living with PH today. For example, demonstrating the benefits of the drug sildenafil – one of the most prescribed medicines in the treatment of PH.
Improving patients’ lives
Without treatment, around only 3 in 10 people with severe PH survive 5 years after diagnosis. BHF-funded research has helped to identify new therapies which have improved the survival rate and quality of life of people with severe PH.
Building NHS capacity
In 2002, BHF Professor Glennis Haworth founded the UK Pulmonary Hypertension Service for Children – a clinical network to help find the best treatments for children with PH. Professor Haworth’s work has been key to improving the survival rates of these children.
Download the report with references and supplementary information
First published 20th June 2022